When will CVS start covering Zepbound and Foundayo?
Zepbound coverage begins October 1, 2026, and Foundayo coverage starts June 1, 2026.
Yanuki
ARTICLE DETAIL
CVS Adds Zepbound and Foundayo to Drug Plans | Trump Endorses Narrower Childhood Vaccine Recommendations | Psychology as a Trench and Embrace: Understanding Its Evolving Role | Mom's Hug Led to Daughter's Breast Cancer Diagnosis | Utah Measles Outbreak: Cases Slowing, but Vigilance Remains | Trump Order Endorses Plan to Halve Vaccines Recommended for Children | Norovirus Outbreak Spreading Across the U.S.: What You Need to Know | UnitedHealthcare Cuts Prior Authorization Requirements for Pediatric Services | Back-to-School Vaccination Guide for Indy and Pasadena | CVS Adds Zepbound and Foundayo to Drug Plans | Trump Endorses Narrower Childhood Vaccine Recommendations | Psychology as a Trench and Embrace: Understanding Its Evolving Role | Mom's Hug Led to Daughter's Breast Cancer Diagnosis | Utah Measles Outbreak: Cases Slowing, but Vigilance Remains | Trump Order Endorses Plan to Halve Vaccines Recommended for Children | Norovirus Outbreak Spreading Across the U.S.: What You Need to Know | UnitedHealthcare Cuts Prior Authorization Requirements for Pediatric Services | Back-to-School Vaccination Guide for Indy and Pasadena
Health / Pharmaceuticals
CVS Adds Zepbound and Foundayo to Drug Plans
CVS Health is reinstating coverage for Eli Lilly's Zepbound and adding coverage for the anti-obesity pill Foundayo, expanding weight-loss treatment options for millions of Americans with private insurance. This move positions Lilly and Novo...
Key Insights
- CVS will reinstate Zepbound coverage starting October 1, 2026, and begin covering Foundayo on June 1, 2026.
- Both Lilly's and Novo Nordisk's GLP-1 medications will be co-preferred options on CVS Caremark's standard commercial formulary.
- This decision aims to provide more affordable and optional weight-loss drug choices for customers.
- Employers are grappling with rising healthcare costs, with pharmacy expenses increasing nearly 15% in 2026 due to GLP-1 medications.
- CVS expects this expanded coverage to drive an additional 10% to 15% savings across the weight management category.
In-Depth Analysis
CVS Caremark's decision to reinstate Zepbound and add Foundayo reflects a strategic effort to balance cost management with patient access to effective weight-loss medications. This move comes a year after CVS initially favored Novo Nordisk's Wegovy, indicating a shift towards a more competitive landscape. The inclusion of both Lilly and Novo Nordisk drugs as co-preferred options on the standard formulary means that insurers and employers can choose to adopt these options, impacting approximately 25 million to 30 million Americans.
The rising cost of healthcare, particularly pharmacy expenses driven by GLP-1 medications, is a significant concern for employers. By negotiating more affordable costs with manufacturers, CVS aims to alleviate some of this financial pressure while providing valuable treatment options.
**Actionable Takeaways:** - Check with your insurance provider or employer to see if Zepbound and Foundayo are covered under your plan. - Consult with your doctor to determine the most appropriate weight-loss treatment option for you. - Be aware that coverage may vary depending on the specific formulary adopted by your employer or insurer.
FAQ
Will my insurance cover these weight-loss drugs?
Coverage depends on whether your employer or insurer adopts CVS Caremark's standard formulary and whether they opt to include GLP-1 medications for weight loss.
Are there alternative ways to access these medications if my insurance doesn't cover them?
Yes, Novo and Lilly have slashed prices for consumers whose insurance plans don't cover weight-loss medications. Cash-paying customers can buy Wegovy or Zepbound from the pharmaceutical companies, telehealth portals, or retailers.
Takeaways
- CVS is expanding coverage to include both Zepbound and Foundayo, offering more weight-loss treatment choices.
- This move aims to drive competition and affordability in the weight-loss drug market.
- Employers and insurers play a key role in determining coverage for these medications.
- Rising healthcare costs are a concern, but CVS is working to negotiate better prices with manufacturers.
Discussion
What are your thoughts on CVS's decision to expand coverage for weight-loss drugs? Share your experiences and opinions in the comments below!
Share this article with others who need to stay ahead of this trend!
Sources
Disclaimer
This article was compiled by Yanuki using publicly available data and trending information. The content may summarize or reference third-party sources that have not been independently verified. While we aim to provide timely and accurate insights, the information presented may be incomplete or outdated.
All content is provided for general informational purposes only and does not constitute financial, legal, or professional advice. Yanuki makes no representations or warranties regarding the reliability or completeness of the information.
This article may include links to external sources for further context. These links are provided for convenience only and do not imply endorsement.
Always do your own research (DYOR) before making any decisions based on the information presented.